The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Myasthenia Gravis: Passive Transfer from Man to Mouse
Abstract
Daily injections into mice of an ammonium sulfate-precipitated immunoglobulin fraction of serum from patients with myasthenia gravis were carried out for up to 14 days. The mice showed reduced amplitudes of miniature endplate potentials and reduced numbers of acetylcholine receptors at the neuromuscular junctions. Some mice showed typical decremental responses on repetitive nerve stimulation, with reversal by neostigmine. This represents the first evidence of a circulating factor in the serum of patients with myasthenia gravis which on passive transfer reproduces features of the disease in experimental animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autoimmune Response to Acetylcholine Receptor
Patrick, J., & Lindstrom, J. (1973) · Science · doi:10.1126/science.180.4088.871 · Cited by 1,043
Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors
Fambrough, D. M., Drachman, D. B., & Satyamurti, S. (1973) · Science · doi:10.1126/science.182.4109.293 · Cited by 640
Myasthenia Gravis: A New Hypothesis
Simpson, J. A. (1960) · Scottish Medical Journal · doi:10.1177/003693306000501001 · Cited by 583
On the factors which determine the amplitude of the ‘miniature end‐plate potential’
Katz, B., & Thesleff, S. (1957) · The Journal of Physiology · doi:10.1113/jphysiol.1957.sp005811 · Cited by 465
FACTORS CONTROLLING SERUM γ-GLOBULIN CONCENTRATION
Fahey, J. L., & Robinson, A. G. (1963) · The Journal of Experimental Medicine · doi:10.1084/jem.118.5.845 · Cited by 173
Determination of Thiocyanate in Blood Serum
Stöa, K. F. (1953) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365515309093504 · Cited by 109
Cited by
Gilhus, N. E., Tzartos, S., Evoli, A., Palace, J., Burns, T. M., & Verschuuren, J. J. G. M. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0079-y · Cited by 953
Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo
Bradl, M., Misu, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., Adzemovic, M., Bauer, J., Berger, T., Fujihara, K., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21837 · Cited by 563
Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis
Higuchi, O., Hamuro, J., Motomura, M., & Yamanashi, Y. (2011) · Annals of Neurology · doi:10.1002/ana.22312 · Cited by 535
Paraneoplastic Cerebellar Ataxia Due to Autoantibodies against a Glutamate Receptor
Smitt, P. S., Kinoshita, A., De Leeuw, B., Moll, W., Coesmans, M., Jaarsma, D., Henzen-Logmans, S., Vecht, C., De Zeeuw, C., Sekiyama, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001063420104 · Cited by 451
Myasthenic Antibodies Cross-Link Acetylcholine Receptors to Accelerate Degradation
Drachman, D. B., Angus, C. W., Adams, R. N., Michelson, J. D., & Hoffman, G. J. (1978) · New England Journal of Medicine · doi:10.1056/nejm197805182982004 · Cited by 437
Myasthenia Gravis: Study of Humoral Immune Mechanisms by Passive Transfer to Mice
Toyka, K. V., Drachman, D. B., Griffin, D. E., Pestronk, A., Winkelstein, J. A., Fischbeck, K. H., & Kao, I. (1977) · New England Journal of Medicine · doi:10.1056/nejm197701202960301 · Cited by 436
Self-citationUnravelling the pathogenesis of myasthenia gravis
Vincent, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri916 · Cited by 414
AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME
Lang, B., Wray, D., Newsom-Davis, J., Vincent, A., & Murray, N. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90474-8 · Cited by 366
Hammer, C., Stepniak, B., Schneider, A., Papiol, S., Tantra, M., Begemann, M., Sirén, A.-L., Pardo, L. A., Sperling, S., Mohd Jofrry, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.110 · Cited by 342
Autoantibodies in neurological disease
Prüss, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00543-w · Cited by 319
Melzer, N., Ruck, T., Fuhr, P., Gold, R., Hohlfeld, R., Marx, A., Melms, A., Tackenberg, B., Schalke, B., Schneider-Gold, C., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8045-z · Cited by 292
Diagnostic and clinical classification of autoimmune myasthenia gravis
Berrih-Aknin, S., Frenkian-Cuvelier, M., & Eymard, B. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.003 · Cited by 289
Acetylcholine receptors and myasthenia
Lindstrom, J. M. (2000) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o · Cited by 280
Darnell, R. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4529 · Cited by 279
Passive transfer of fibromyalgia symptoms from patients to mice
Goebel, A., Krock, E., Gentry, C., Israel, M. R., Jurczak, A., Urbina, C. M., Sandor, K., Vastani, N., Maurer, M., Cuhadar, U., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144201 · Cited by 278
“This dose regimen was based on the original studies identifying myasthenia gravis as an autoantibody-mediated disorder (29, 30), and more recent studies of complex regional pain syndrome (26, 31).”
BackgroundHelyes, Z., Tékus, V., Szentes, N., Pohóczky, K., Botz, B., Kiss, T., Kemény, Á., Környei, Z., Tóth, K., Lénárt, N., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820168116 · Cited by 122
“Limitations include the upper transfer limit cutoff at 13 d, which was necessary to avoid the adverse effects of serum sickness (37).”
BackgroundAutoantibodies produce pain in complex regional pain syndrome by sensitizing nociceptors
Cuhadar, U., Gentry, C., Vastani, N., Sensi, S., Bevan, S., Goebel, A., & Andersson, D. A. (2019) · Pain · doi:10.1097/j.pain.0000000000001662 · Cited by 74
Metadata
- Authors
- Toyka, K. V., Brachman, D. B., Pestronk, A., & Kao, I.
- Venue
- Science
- Published
- 1975-10-24
- Volume
- 190
- Issue
- 4212
- Pages
- 397-399
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2044625734
- Cited by
- 441
- References
- 6
- FWCI
- 19.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.